200 related articles for article (PubMed ID: 24751157)
1. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
5. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
6. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
[TBL] [Abstract][Full Text] [Related]
7. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
13. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel non-covalent piperidine-containing peptidyl proteasome inhibitors.
Zhang J; Gao L; Xi J; Sheng L; Zhao Y; Xu L; Shao Y; Liu S; Zhuang R; Zhou Y; Li J
Bioorg Med Chem; 2016 Dec; 24(23):6206-6214. PubMed ID: 27765408
[TBL] [Abstract][Full Text] [Related]
17. Total synthesis and absolute stereochemistry of the proteasome inhibitors cystargolides A and B.
Tello-Aburto R; Hallada LP; Niroula D; Rogelj S
Org Biomol Chem; 2015 Oct; 13(40):10127-30. PubMed ID: 26400369
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
19. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
Bioorg Med Chem; 2014 Jun; 22(12):3091-5. PubMed ID: 24814885
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]